PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

Cariprazine 1.5 mg Adjunct Beats Placebo in Inadequate-Response Depression

cariprazineatypical antipsychoticdopamine D3-preferring partial agonistmajor depressive disorderadjunctive therapyrandomized controlled trialphase 3akathisiapsychopharmacology Psychiatry / Psychopharmacology

Background Information

Cariprazine 1.5 mg/day shows promise for unmet depression needs.

Many patients with major depressive disorder (MDD) do not respond to antidepressants alone, necessitating effective adjunctive treatment options. Cariprazine 1.5 mg/day significantly improved depression scores compared to placebo and showed greater response rates at week 6. Cariprazine at 1.5 mg/day is effective as an adjunct for MDD, but 3 mg/day did not achieve significance. Safety was consistent with other uses. Cariprazine 1.5 mg/day is effective and well-tolerated for adjunctive MDD treatment.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Sachs GS, Yeung PP, Rekeda L, Khan A, Adams JL, Fava M

Citation: Sachs GS, Yeung PP, Rekeda L, et al. Cariprazine for the Adjunctive Treatment of Major Depressive Disorder: Results of a Randomized Phase 3 Placebo-Controlled Study (Study 301). CNS spectrums. 2023;28(2):254-255. doi:10.1017/S1092852923001980

Article Links: PubMed · Journal / DOI

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.